{"success":true,"data":{"pressRelease":{"id":"93766","rtpr_id":"nGNX1DjfHG","ticker":"VRCA","exchange":"NASDAQ","all_tickers":["VRCA"],"title":"Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel","author":"Globe Newswire","published_at":"2026-07-21T12:00:01.764Z","article_body":"WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals\nInc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and\ncommercializing medications for the treatment of dermatological diseases,\nincluding skin cancers, today announced an exclusive distribution, marketing\nand supply agreement (“the Agreement”) granting Medomie Pharma Ltd.\n(“Medomie”) rights to seek regulatory approval for and distribute\nYCANTH(®) for the treatment of molluscum contagiosum (“molluscum”) in\nIsrael.\n\n“We are pleased to partner with Medomie to make YCANTH available in Israel\nso that more patients have access to treatment for molluscum,” said Jayson\nRieger, PhD, MBA, President and Chief Executive Officer of Verrica. “Medomie\nis a pharmaceutical company focused on providing access to and commercializing\ninnovative treatments, and improving health and quality of life of patients in\nIsrael. We look forward to working with them as we seek to establish YCANTH as\nthe standard of care for molluscum in Israel. Verrica maintains exclusive\nglobal rights to YCANTH for all indications outside of Japan and Israel, and\nwe will continue our work to bring YCANTH to patients with molluscum around\nthe world,” Dr. Rieger continued.\n\nUnder the terms of the Agreement, Verrica has granted Medomie an exclusive\nright to obtain and maintain marketing authorizations for YCANTH in Israel.\nVerrica will manufacture YCANTH and provide commercial supply to Medomie and\nwill receive 60% of the net selling price of product sold by Medomie in\nIsrael. Verrica is also eligible to receive up to $8.2 million in total\nregulatory and commercial milestones.\n\nAbout YCANTH(®) (VP-102) \nYCANTH(®) is a proprietary drug-device combination product that contains a\nGMP-controlled formulation of cantharidin delivered via a single-use\napplicator that allows for precise topical dosing and targeted administration\nfor the treatment of molluscum. YCANTH is the first and only healthcare\nprofessional-administered product approved by the FDA to treat adult and\npediatric patients two years of age and older with molluscum contagiosum — a\ncommon, highly contagious skin disease that affects an estimated six million\npeople in the United States, primarily children. Approval of YCANTH in the US\nwas based upon the positive results from two Phase 3 clinical trials in\napproximately 500 patients which demonstrated that YCANTH was a safe and\neffective therapeutic for the treatment of molluscum. Approximately 250\nmillion lives are eligible to receive YCANTH covered by insurance.\nCommercially insured patients pay just $25 per YCANTH treatment visit, for up\nto two applicators. Other uninsured patients may be eligible to receive YCANTH\nat a reduced cost if certain eligibility requirements are met for patient\nassistance. Please visit YCANTHPro.com for additional information.  \n\nYCANTH is now approved for the treatment of molluscum contagiosum in Japan\nbased upon an additional Phase 3 trial of approximately 300 patients. YCANTH\nis also now being studied in a global phase 3 program in the US and Japan for\nuse in the treatment of common warts.\n\nAbout Verrica Pharmaceuticals Inc. \nVerrica is a therapeutics company developing and commercializing medications\nfor the treatment of dermatological diseases, including skin cancers.\nVerrica’s product YCANTH(®) (VP-102) (cantharidin), is the first and only\nhealthcare professional-administered treatment approved by the FDA to treat\nadult and pediatric patients two years of age and older with molluscum\ncontagiosum, a highly contagious viral skin infection affecting approximately\n6 million people in the United States, primarily children.\nYCANTH(®) (VP-102) is also in development to treat common warts, the largest\nremaining unmet need in medical dermatology. Verrica has also entered a\nworldwide license agreement with Lytix Biopharma AS to develop and\ncommercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315)\nfor non-melanoma skin cancers including basal cell carcinoma and squamous cell\ncarcinoma.  For more information, visit www.verrica.com.\n\nForward-Looking Statements \nAny statements contained in this press release that do not describe historical\nfacts may constitute forward-looking statements as that term is defined in the\nPrivate Securities Litigation Reform Act of 1995. These statements may be\nidentified by words such as “believe,” “expect,” “may,”\n“plan,” “potential,” “will,” and similar expressions, and are\nbased on Verrica’s current beliefs and expectations. These forward-looking\nstatements include statements about seeking regulatory approval and\ncommercializing YCANTH in Israel, potential future payments pursuant to the\nAgreement and the clinical development and potential benefits of Verrica’s\nproduct candidates, including YCANTH (VP-102) and VP-315. These statements\ninvolve risks and uncertainties that could cause actual results to differ\nmaterially from those reflected in such statements. Risks and uncertainties\nthat may cause actual results to differ materially include risks and\nuncertainties related to market conditions and other risks and uncertainties\nthat are described in Verrica’s Annual Report on Form 10-K for the year\nended December 31, 2025, Verrica’s Quarterly Reports on Form 10-Q and other\nfilings Verrica makes with the SEC. Any forward-looking statements speak only\nas of the date of this press release and are based on information available to\nVerrica as of the date of this release, and Verrica assumes no obligation to,\nand does not intend to, update any forward-looking statements, whether as a\nresult of new information, future events or otherwise.\n\nFOR MORE INFORMATION, PLEASE CONTACT:\n\nInvestors:\n\nJohn Kirby\nInterim Chief Financial Officer\njkirby@verrica.com\n\nKevin Gardner\nLifeSci Advisors\nkgardner@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1DjfHG","title":"Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel","author":"Globe Newswire","ticker":"VRCA","created":"2026-07-21T12:00:01.764Z","tickers":["VRCA"],"exchange":"NASDAQ","article_body":"WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals\nInc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and\ncommercializing medications for the treatment of dermatological diseases,\nincluding skin cancers, today announced an exclusive distribution, marketing\nand supply agreement (“the Agreement”) granting Medomie Pharma Ltd.\n(“Medomie”) rights to seek regulatory approval for and distribute\nYCANTH(®) for the treatment of molluscum contagiosum (“molluscum”) in\nIsrael.\n\n“We are pleased to partner with Medomie to make YCANTH available in Israel\nso that more patients have access to treatment for molluscum,” said Jayson\nRieger, PhD, MBA, President and Chief Executive Officer of Verrica. “Medomie\nis a pharmaceutical company focused on providing access to and commercializing\ninnovative treatments, and improving health and quality of life of patients in\nIsrael. We look forward to working with them as we seek to establish YCANTH as\nthe standard of care for molluscum in Israel. Verrica maintains exclusive\nglobal rights to YCANTH for all indications outside of Japan and Israel, and\nwe will continue our work to bring YCANTH to patients with molluscum around\nthe world,” Dr. Rieger continued.\n\nUnder the terms of the Agreement, Verrica has granted Medomie an exclusive\nright to obtain and maintain marketing authorizations for YCANTH in Israel.\nVerrica will manufacture YCANTH and provide commercial supply to Medomie and\nwill receive 60% of the net selling price of product sold by Medomie in\nIsrael. Verrica is also eligible to receive up to $8.2 million in total\nregulatory and commercial milestones.\n\nAbout YCANTH(®) (VP-102) \nYCANTH(®) is a proprietary drug-device combination product that contains a\nGMP-controlled formulation of cantharidin delivered via a single-use\napplicator that allows for precise topical dosing and targeted administration\nfor the treatment of molluscum. YCANTH is the first and only healthcare\nprofessional-administered product approved by the FDA to treat adult and\npediatric patients two years of age and older with molluscum contagiosum — a\ncommon, highly contagious skin disease that affects an estimated six million\npeople in the United States, primarily children. Approval of YCANTH in the US\nwas based upon the positive results from two Phase 3 clinical trials in\napproximately 500 patients which demonstrated that YCANTH was a safe and\neffective therapeutic for the treatment of molluscum. Approximately 250\nmillion lives are eligible to receive YCANTH covered by insurance.\nCommercially insured patients pay just $25 per YCANTH treatment visit, for up\nto two applicators. Other uninsured patients may be eligible to receive YCANTH\nat a reduced cost if certain eligibility requirements are met for patient\nassistance. Please visit YCANTHPro.com for additional information.  \n\nYCANTH is now approved for the treatment of molluscum contagiosum in Japan\nbased upon an additional Phase 3 trial of approximately 300 patients. YCANTH\nis also now being studied in a global phase 3 program in the US and Japan for\nuse in the treatment of common warts.\n\nAbout Verrica Pharmaceuticals Inc. \nVerrica is a therapeutics company developing and commercializing medications\nfor the treatment of dermatological diseases, including skin cancers.\nVerrica’s product YCANTH(®) (VP-102) (cantharidin), is the first and only\nhealthcare professional-administered treatment approved by the FDA to treat\nadult and pediatric patients two years of age and older with molluscum\ncontagiosum, a highly contagious viral skin infection affecting approximately\n6 million people in the United States, primarily children.\nYCANTH(®) (VP-102) is also in development to treat common warts, the largest\nremaining unmet need in medical dermatology. Verrica has also entered a\nworldwide license agreement with Lytix Biopharma AS to develop and\ncommercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315)\nfor non-melanoma skin cancers including basal cell carcinoma and squamous cell\ncarcinoma.  For more information, visit www.verrica.com.\n\nForward-Looking Statements \nAny statements contained in this press release that do not describe historical\nfacts may constitute forward-looking statements as that term is defined in the\nPrivate Securities Litigation Reform Act of 1995. These statements may be\nidentified by words such as “believe,” “expect,” “may,”\n“plan,” “potential,” “will,” and similar expressions, and are\nbased on Verrica’s current beliefs and expectations. These forward-looking\nstatements include statements about seeking regulatory approval and\ncommercializing YCANTH in Israel, potential future payments pursuant to the\nAgreement and the clinical development and potential benefits of Verrica’s\nproduct candidates, including YCANTH (VP-102) and VP-315. These statements\ninvolve risks and uncertainties that could cause actual results to differ\nmaterially from those reflected in such statements. Risks and uncertainties\nthat may cause actual results to differ materially include risks and\nuncertainties related to market conditions and other risks and uncertainties\nthat are described in Verrica’s Annual Report on Form 10-K for the year\nended December 31, 2025, Verrica’s Quarterly Reports on Form 10-Q and other\nfilings Verrica makes with the SEC. Any forward-looking statements speak only\nas of the date of this press release and are based on information available to\nVerrica as of the date of this release, and Verrica assumes no obligation to,\nand does not intend to, update any forward-looking statements, whether as a\nresult of new information, future events or otherwise.\n\nFOR MORE INFORMATION, PLEASE CONTACT:\n\nInvestors:\n\nJohn Kirby\nInterim Chief Financial Officer\njkirby@verrica.com\n\nKevin Gardner\nLifeSci Advisors\nkgardner@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-21T12:00:02.267536933Z","server_sent_at_ms":1784635202267},"received_at":"2026-07-21T12:00:02.318Z","source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330404/0/en/Verrica-Pharmaceuticals-and-Medomie-Pharma-Enter-into-Exclusive-Distribution-Marketing-and-Supply-Agreement-to-Commercialize-YCANTH-for-the-Treatment-of-Molluscum-Contagiosum-in-Is.html"},"analysis":{"id":"82810","press_release_id":"93766","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Verrica entered an exclusive distribution agreement with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel. Verrica will manufacture and supply the product, while Medomie seeks local regulatory approval and manages marketing.\n\nFinancial terms provide Verrica with 60% of the net selling price of product sold in Israel. Verrica is also eligible to receive up to $8.2 million in total regulatory and commercial milestones.\n\nYCANTH is the first FDA-approved healthcare professional-administered treatment for molluscum and is currently approved in the US and Japan.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Verrica expands YCANTH footprint to Israel via exclusive deal, securing 60% revenue share and $8.2M in milestones."},"keyFigures":{"customDimensions":{"total_milestones":8200000,"revenue_share_percent":60}},"quotedText":"We are pleased to partner with Medomie to make YCANTH available in Israel so that more patients have access to treatment for molluscum","namedEntities":{"people":[{"name":"Jayson Rieger","role":"President and Chief Executive Officer"},{"name":"John Kirby","role":"Interim Chief Financial Officer"},{"name":"Kevin Gardner","role":"Investor Contact"}],"products":["YCANTH","VP-102","VP-315","ruxotemitide"],"companies":[{"name":"Medomie Pharma Ltd.","relationship":"distribution partner"},{"name":"Lytix Biopharma AS","relationship":"licensing partner"},{"name":"LifeSci Advisors","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$8.2 million","context":"total regulatory and commercial milestones"}]},"materialImpact":{"score":3,"reasoning":"Exclusive distribution agreement expands commercial reach for approved asset YCANTH into Israel with defined financial terms (60% revenue share, up to $8.2M milestones). While the market is smaller than the US, the deal validates international demand and adds a near-term revenue stream."},"tickerRelevance":{"others":[],"primary":"VRCA"},"globalImportance":20,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_cap","eventGravity":"commercial_partnership","sectorWeight":"biotech"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Verrica entered an exclusive distribution agreement with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel. Verrica will manufacture and supply the product, while Medomie seeks local regulatory approval and manages marketing.\n\nFinancial terms provide Verrica with 60% of the net selling price of product sold in Israel. Verrica is also eligible to receive up to $8.2 million in total regulatory and commercial milestones.\n\nYCANTH is the first FDA-approved healthcare professional-administered treatment for molluscum and is currently approved in the US and Japan.","key_figures":{"customDimensions":{"total_milestones":8200000,"revenue_share_percent":60}},"named_entities":{"people":[{"name":"Jayson Rieger","role":"President and Chief Executive Officer"},{"name":"John Kirby","role":"Interim Chief Financial Officer"},{"name":"Kevin Gardner","role":"Investor Contact"}],"products":["YCANTH","VP-102","VP-315","ruxotemitide"],"companies":[{"name":"Medomie Pharma Ltd.","relationship":"distribution partner"},{"name":"Lytix Biopharma AS","relationship":"licensing partner"},{"name":"LifeSci Advisors","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$8.2 million","context":"total regulatory and commercial milestones"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-21T13:52:07.489Z","global_importance":20,"audience_relevance":15,"importance_components":{"tickerTier":"small_cap","eventGravity":"commercial_partnership","sectorWeight":"biotech"}},"durationMs":260279,"modelName":"glm-4.7"}}